【摘要】 目的观察和分析FOLFOX4方案一线治疗晚期大肠癌的近期疗效和毒副作用。方法31例晚期大肠癌患者接受OXA85mg/m2静脉点滴2小时,第1天;CF200mg/m2静脉点滴2小时,5-FU400mg/m2静脉推注后续以600mg/m2持续静脉点滴22小时,第1、2天;2周重复,为1周期。应用4~6周期后判定疗效。结果31例患者平均治疗周期数9·2个,其中CR2例,PR13例,SD14例,总有效率为48·4%,疾病控制率为93·5%,中位至疾病进展时间为9·0个月。单因素分析时CR+PR组较SD+PD组转移部位数目少、肝转移比例高、肺转移比例低;回归分析中仅肝转移影响有效性。骨髓抑制为主要毒副作用,粒细胞下降达80·6%,其次是胃肠道反应、周围神经毒性。结论FOLFOX4方案一线治疗晚期大肠癌,尤其是肝转移患者有较好疗效,毒性反应可耐受。更多还原

【Abstract】 Objective The short-term efficacy and toxicity of FOLFOX4 was evaluated for treating patients with advanced colorectal carcinoma as the first-line chemotherapy.Methods Oxaliplatin 85mg/m~2 iv infusion for 2 hours,d1;CF200mg/m~2 iv infusion for 2 hours followed by 5-FU 400mg/m~2 iv bolus and 600mg/m~2 iv infusion for 22 hours,d1-2.Every two weeks was a cycle.Patients were evaluated after 4-6 cycles.Results 31 patients who were experienced 9.2 cycles averagely entered this study:CR 2 cases,PR 13 cases,SD 14 cases.The overall response rate was 44.8%,and the disease control rate 93.5%.Univariate analysis indicated the less numbers of metastatic sites,higher ratio of liver metastasis,and lower ratio of lung metastasis in the CR+PR group than SD+PD group.Regression analysis showed only liver metastasis had an independent effect on the efficacy.The main adverse effects were myelosuppression.Neutropenia was 80.6%,nausea/vomiting 51.6%,neurosensory toxicity 35.5%.Conclusion FOLFOX4 was effective for the first-line chemotherapy of advanced colorectal carcinoma,especially those with liver metastasis,and the toxicity was mild and tolerable.更多还原